Home > Boards > US Listed > Biotechs >

Intec Pharma Ltd. (NTEC)

NTEC RSS Feed
Add NTEC Price Alert      Hide Sticky   Hide Intro
Moderator: Brian903
Search This Board: 
Last Post: 10/4/2019 5:14:49 PM - Followers: 22 - Board type: Free - Posts Today: 0

Intec Pharma

https://www.intecpharma.com/


Developing Drugs Based on the Accordion Pill Platform

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill® (AP) platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.

Intec’s strategy is to leverage its proprietary delivery technology to improve the properties of known/approved compounds, with plans to partner these for full development and commercialization. Intec also plans to work in collaboration with biotechnology and pharmaceutical companies to develop novel delivery systems for their proprietary drugs, including existing compounds undergoing lifecycle management.

The Company’s product pipeline includes four candidates in clinical development:

Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which recently completed a Phase 3 trial for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and
AP-cannabinoids, early stage development of a system to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various indications including cancer pain and opioid-sparing pain management.

Clinical Programs Currently in Development


Management

Jeffrey A. Meckler

CEO and Vice Chairman of the Board

Mr. Meckler joined our Board in April 2017 as Vice Chairman and was appointed Chief Executive Officer in July 2017.  Mr. Meckler brings more than 25 years of financial and healthcare experience, having held a variety of senior leadership roles in both large and small biopharma companies. Mr. Meckler started his career in life sciences at Pfizer, Inc. During his 17 years at Pfizer, Mr. Meckler rose through a series of positions eventually becoming a member of the Corporate Finance Leadership Team overseeing a number of acquisition and divestitures.  Most recently, Mr. Meckler was the CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company.  Additionally, Mr. Meckler led QLT, Inc., Cypress Bioscience, Inc. and Retrophin, Inc. through transformational times.  Mr. Meckler has served on the board of a number of private and public companies and is currently a director and former Chairman of Retrophin.  Mr. Meckler holds a B.S. in Industrial Management and a M.S. in Industrial Administration from the Tepper School of Business at Carnegie Mellon University.  Additionally, he received his J.D. from Fordham University’s School of Law.

Nadav Navon, Ph.D.

Chief Operating Officer

Dr. Nadav Navon has been with us since March 2006 and has served as our COO since July 2017. Before that he served as our Executive Vice President of Research & Development and Operations since March 2015. Prior to his service with us, Dr. Navon headed the analytical and quality assurance operations at Sharon Laboratories Ltd., a chemical company that develops and manufactures raw materials for the pharmaceutical, cosmetic and food industries, from 2001 to 2006. Prior to that, Dr. Navon led a number of research and development projects in the Negev’s Nuclear Research Center. Dr. Navon has a Ph.D. in inorganic and analytical chemistry, and an MBA and a BSc in chemistry, each from Ben-Gurion University in Beer-Sheva, Israel.

Nir Sassi

Chief Financial Officer

Mr. Nir Sassi has been our Chief Financial Officer since August 2016. Prior to serving as our Chief Financial Officer, he served as our VP Finance commencing in March 2010. Prior to his service with us, Mr. Sassi served as a Senior Manager at PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2010, including two years relocation to the PricewaterhouseCoopers New York office. Mr. Sassi is a certified public accountant in Israel and has a bachelor’s degree in economics and accounting from Ben Gurion University in Beer Sheva, Israel.

R. Michael Gendreau, M.D., Ph.D.

Chief Medical Officer

Dr. R. Michael Gendreau was named as our Chief Medical Officer in February 2018. Prior to joining Intec, Dr. Gendreau founded a consulting firm providing strategic advice on the design and management of clinical programs, strategic planning, and technology assessments for emerging pharmaceutical, diagnostic, and medical device companies. He has served on various scientific advisory boards, executive strategic planning boards, and Data Safety Monitoring Boards. Prior to his consulting career, Dr. Gendreau served from 1996 until 2011 as Chief Medical Officer at Cypress Bioscience, Inc., a clinical-stage biotech company developing therapies for central nervous system disorders. Prior to Cypress Bioscience, Dr. Gendreau was Chief Medical Officer of Microprobe Corporation from 1991 to 1994. Additionally, he has served as Chief Medical Officer at other institutions including Battelle Memorial Institute. Dr. Gendreau received his B.S. in Chemistry from Ohio University, and earned his M.D./Ph.D. from The Ohio State University.

Walt A. Linscott

Chief Business Officer

Mr. Linscott brings three decades of global leadership, entrepreneurial and professional experience with broad business development, operational, regulatory, and transactional experience in the Life Sciences sector. He is co-founder of a global consulting enterprise providing strategic advice to developing companies and has served as General Counsel and Corporate Secretary to public and private medical device and pharmaceutical companies including Cocrystal Pharma, Inc., Carestream Health, Inc. and Solvay Pharmaceuticals, Inc. where he also led compliance, IP, security, privacy, public affairs and government affairs functions.  In addition, he was an associate and partner at Thompson Hine LLP for seventeen years collectively where he founded the firm’s Atlanta office, served as Partner in Charge and Chair of the firm’s Life Science Practice Group.  Mr. Linscott holds a Postgraduate Diploma in Global Business from the University of Oxford and has recently completed a Postgraduate Diploma in Entrepreneurship from Cambridge University.  He earned a Juris Doctor from the University of Dayton School of Law where he served as Managing Editor of the Law Review.  After graduating with a bachelor’s degree from Syracuse University and prior to entering law school, he earned a commission and served on active duty as an Officer in the United States Marine Corps.

 

Board of Directors

 

John W. Kozarich, Ph.D.

Chairman of the Board

Dr. Kozarich has been our Chairman of the Board of directors since July 2016. Dr. Kozarich has nearly 40 years of experience in the biopharmaceutical industry and academia. Dr. Kozarich currently serves as Chairman of Ligand Pharmaceuticals. From 2004 until April 2017, Dr. Kozarich served as Chairman and President of ActivX Biosciences, Inc., or ActivX, where he is now a Distinguished Scientist. Prior to his role at ActivX, Dr. Kozarich was Vice President at Merck Research Laboratories where he was responsible for a variety of drug discovery and development programs and external biotech collaborations. Dr. Kozarich previously held full professorships at the University of Maryland and Yale School of Medicine. He was named Director of the Year for 2014 by the Corporate Directors Forum, has been an American Cancer Society Faculty Research Awardee, and received the Distinguished Scientist Award of the San Diego Section of the American Chemical Society. Dr. Kozarich holds a B.S. in chemistry from Boston College and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology and was an NIH Postdoctoral Fellow at Harvard University.

Jeffrey A. Meckler

CEO and Vice Chairman of the Board

Mr. Meckler joined our Board in April 2017 as Vice Chairman and was appointed Chief Executive Officer in July 2017.  Mr. Meckler brings more than 25 years of financial and healthcare experience, having held a variety of senior leadership roles in both large and small biopharma companies. Mr. Meckler started his career in life sciences at Pfizer, Inc. During his 17 years at Pfizer, Mr. Meckler rose through a series of positions eventually becoming a member of the Corporate Finance Leadership Team overseeing a number of acquisition and divestitures.  Most recently, Mr. Meckler was the CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company.  Additionally, Mr. Meckler led QLT, Inc., Cypress Bioscience, Inc. and Retrophin, Inc. through transformational times.  Mr. Meckler has served on the board of a number of private and public companies and is currently a director and former Chairman of Retrophin.  Mr. Meckler holds a B.S. in Industrial Management and a M.S. in Industrial Administration from the Tepper School of Business at Carnegie Mellon University.  Additionally, he received his J.D. from Fordham University’s School of Law.

Gil Bianco

Mr. Gil Bianco has served as one of our directors since April 2010. From November 2009 to November 2012, Mr. Bianco served as a director of D-Pharm Ltd., an Israeli public biopharmaceutical company, and from May 2007 to May 2010, Mr. Bianco served as a director of BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical development company. From December 2003 to December 2009, Mr. Bianco served as an external director of the Tel Aviv Stock Exchange Ltd. Prior to that, from 2001 to 2003, Mr. Bianco served as chief executive officer of Agis Industries Ltd., a pharmaceutical manufacturer. Mr. Bianco currently serves as an external director at Mazor Robotics Ltd. (NASDAQ: MZOR and TASE: MZOR.TA), a medical device company. Mr. Bianco is also a director of several private companies in the fields of biotech and medical devices. Mr. Bianco holds a B.A. in economics and accounting from Tel-Aviv University in Tel-Aviv, Israel and is a certified public accountant in Israel.

Brad Hayes

Mr. Hayes joined our Board in July 2018.  Most recently, Mr. Hayes was Executive Vice President, Chief Financial Officer and Treasurer of Laboratory Corporation of America Holdings (LabCorp), a diagnostics laboratory company with current annual revenue of approximately $10 billion.  Mr. Hayes joined LabCorp in 1996, where he was responsible for day-to-day operations of the revenue cycle function. He rose through a series of promotions and in 2005 was named Executive Vice President, Chief Financial Officer and Treasurer of LabCorp, a role he held until his retirement in 2014.  Prior to LabCorp, Mr. Hayes was at KPMG for nine years in their audit department.  Mr. Hayes served as a director for Patheon N.V., a pharmaceutical manufacturing company with approximately $2 billion in annual revenue, until its acquisition by Thermo Fisher in late 2017.  Mr. Hayes holds a Bachelor of Science in accounting from the University of North Carolina at Greensboro and is a Certified Public Accountant.

Hila Karah

Ms. Hila Karah has served as one of our directors since December 2009. Ms. Karah is the executive chairperson of FloraFotonica Ltd., an Israeli Agro Tech startup. Ms. Karah is an experienced board director and independent business consultant to private and public companies on strategy, operations, financing, regulatory and corporate governance. From 2006 until 2013, Ms. Karah was the chief investment officer of Eurotrust Ltd., a family office, where she focused primarily on investments in life science, internet and high-tech companies. Prior to joining Eurotrust, Ms. Karah served as a senior analyst at Perceptive Life Sciences Ltd., a New York-based hedge fund. Prior to her position at Perceptive, Ms. Karah was a research analyst at Oracle Partners Ltd., a healthcare-focused hedge fund based in Connecticut. Ms. Karah currently serves as a director at Cyren Ltd. a cyber security company (NASDAQ, TASE: CYRN), a director at Dario Health Corp., (NASDAQ: DRIO) a board observer at MyHeritage Ltd. (private company) and a director at GR Dome Ltd. (private company). She has a B.A. in molecular and cell biology from the University of California, Berkeley, and has studied at the UCSB – UCSF Joint Medical Program.

Anthony J. Maddaluna

Mr. Maddaluna joined our Board in 2017 and brings more than 40 years of experience in the pharmaceutical manufacturing industry at Pfizer, including leadership positions in manufacturing plants both regionally and globally. Mr. Maddaluna held a series of positions at Pfizer Inc., most recently serving as the President of Pfizer Global Supply, a position he served in from 2011 through his retirement in 2017. Prior to that, he served as Senior Vice President of Pfizer Global Manufacturing Strategy and Supply Network Transformation (2008 – 2011), and as Vice President of Pfizer Global Manufacturing Europe Area (1998 – 2008). Mr. Maddaluna holds an M.S. in Chemical Engineering from Northeastern University and an M.B.A. from Southern Illinois University.

Roger J. Pomerantz, M.D.

Dr. Pomerantz joined our Board in March 2018. Dr. Pomerantz currently serves as the President, Chief Executive Officer, and Chairman of the Board of Directors of Seres Therapeutics. Prior to joining Seres, Dr. Pomerantz was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc., where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for J&J. Dr. Pomerantz earned his B.A. in biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his internal medicine internship and residency training, and his subspecialty clinical and research training in infectious diseases and virology at the Massachusetts General Hospital of Harvard Medical School. His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology (MIT). Dr. Pomerantz also served as the Chief Resident at the Massachusetts General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. Dr. Pomerantz is an internationally recognized expert in HIV molecular pathogenesis and latency. He has developed ten approved infectious disease drugs in important diseases including HIV, HCV, tuberculosis, and Clostridium difficile infection.

Issac Silberman

Mr. Issac Silberman has served as one of our directors since April 2010. Since 2007, Mr. Silberman has also served as a special investment advisor at Sullam Holdings L.R. Ltd., a financial services corporation in the Lenny Recanati Group, focusing primarily on investments in high-tech, biotechnology and real estate companies. Mr. Silberman also serves as a director in other private Israeli companies, and has over 20 years of prior experience as an executive officer of various public and private companies. Mr. Silberman holds a B.A. in economics and accounting from Tel Aviv University in Tel Aviv, Israel, and he is a certified public accountant in Israel.

NTEC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTEC News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 10/07/2019 04:52:58 PM
NTEC News: Current Report Filing (8-k) 09/27/2019 04:17:48 PM
NTEC News: Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of... 09/25/2019 07:45:00 AM
NTEC News: Current Report Filing (8-k) 09/16/2019 08:09:10 AM
NTEC News: Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society 09/16/2019 07:00:00 AM
PostSubject
#207  Sticky Note https://ir.intecpharma.com/static-files/6655b5c7-18b3-4ea6-b058-e4ba14aa9641 Brian903 08/20/19 03:14:18 PM
#316   * * $NTEC Video Chart 10-04-2019 * * ClayTrader 10/04/19 05:14:49 PM
#315   True the whole market looks the same so Snowman2 09/27/19 02:53:37 AM
#314   There we go!!! Green!!!! Snowman2 09/26/19 10:11:39 AM
#313   Volume jumped like crazy at the end lol Snowman2 09/25/19 04:26:02 PM
#312   News news news :) Snowman2 09/25/19 11:00:15 AM
#311   Green green green Snowman2 09/25/19 10:49:26 AM
#310   Created an account but completely for got about 8right 09/24/19 06:17:32 PM
#309   You been on ihub for 2 years..new? Snowman2 09/24/19 03:03:44 PM
#308   Won't go anywhere until they stop dilution simmons420 09/24/19 02:36:07 PM
#307   This stock can not move unless this seller simmons420 09/24/19 02:35:21 PM
#306   Great question but let's be real why is Snowman2 09/24/19 01:52:01 PM
#305   Here we go Snowman2 09/24/19 12:54:25 PM
#304   Why did this company go from $9 to 8right 09/23/19 06:08:39 PM
#303   I think I`ll load the boat, down here......$1...$1.01..1.02....all dirtydozen911 09/23/19 03:43:34 PM
#302   There's more bidders than sellers Snowman2 09/23/19 03:40:08 PM
#301   Sellers will leave Snowman2 09/23/19 03:38:23 PM
#300   It will Snowman2 09/23/19 03:38:01 PM
#299   I hope this 1.00 can hold. Would simmons420 09/23/19 02:46:43 PM
#298   Here comes the bounce :) Snowman2 09/23/19 02:35:54 PM
#297   It's about that time for some green Snowman2 09/23/19 11:14:23 AM
#296   $NTEC!! My little orphan. Ha!! ROCKY LEDGE 09/23/19 10:39:57 AM
#295   ....$ntec....slow and steady. : )> ROCKY LEDGE 09/22/19 01:25:36 AM
#294   Nice 12% gain Snowman2 09/20/19 03:09:37 PM
#293   A nice pop for this power hour :) Snowman2 09/20/19 02:59:32 PM
#292   And bounce for this friday Snowman2 09/20/19 02:01:30 PM
#291   Nice buy today Snowman2 09/20/19 02:01:07 PM
#290   ....nice....up again we go....very quiet mover....imho. ROCKY LEDGE 09/20/19 09:49:34 AM
#289   * * $NTEC Video Chart 09-19-2019 * * ClayTrader 09/19/19 04:24:03 PM
#288   Buy more- Novartis will be huge Brian903 09/19/19 04:15:53 PM
#287   changed direction...........now headed down the stairs...hahaha dirtydozen911 09/19/19 01:28:48 PM
#286   buying oppurtunity Brian903 09/18/19 01:13:30 PM
#285   Here we go Snowman2 09/18/19 11:45:27 AM
#284   * * $NTEC Video Chart 09-17-2019 * * ClayTrader 09/17/19 05:37:09 PM
#283   I love these stocks that climb the stairs dirtydozen911 09/17/19 12:36:34 PM
#282   Green green green all bulls here am I right??? Snowman2 09/17/19 11:40:02 AM
#281   Load the boat parrot head 09/17/19 10:52:36 AM
#280   wow $1.49 amazing :) wesley_ 09/17/19 09:47:55 AM
#279   11% gain looking pretty good to me Snowman2 09/16/19 03:34:44 PM
#278   Volume coming back Snowman2 09/16/19 12:48:19 PM
#277   Real news will be Novartis and or Merck Brian903 09/16/19 12:42:38 PM
#276   Waiting to get back in on the consolidation Brian903 09/16/19 12:41:44 PM
#275   Boom? Snowman2 09/16/19 12:18:28 PM
#274   Looks like it's bottomed out Snowman2 09/16/19 11:46:19 AM
#273   All that green oh yeeeeaaaaa!!! Snowman2 09/16/19 11:39:36 AM
#272   News is out yayyyyyuuhhhh Snowman2 09/16/19 11:37:52 AM
#271   Nice Snowman2 09/16/19 10:51:31 AM
#270   Top Penny Stocks To Watch Making Headlines jonny_red 09/16/19 08:57:21 AM
#269   #ShareTheHarvest Webull’s $100,000 Card Harvest Event https://act.webull.com/col Brian903 09/14/19 10:35:48 AM
#268   I bought at .50 sold at .60 but ed66 09/13/19 10:28:13 PM
#267   .44 and sold .88 I did not buy back Brian903 09/13/19 09:19:18 PM
PostSubject